Parvovirus B19 infection modulates the levels of cytokines in the plasma of rheumatoid arthritis patients

Cytokine

Volumn 96, Issue , 2017, Pages 41-48

  Naciute, Milda ^a   Mieliauskaite, Diana ^a   Rugiene, Rita ^a,b   Maciunaite, Gabriele ^a   Mauricas, Mykolas ^a   Murovska, Modra ^c   Girkontaite, Irute ^a  

^a State Research Institute Centre for Innovative Medicine   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

^c RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

IFN ; IL 4; Parvovirus B19; Rheumatoid arthritis

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN VP1; TUMOR NECROSIS FACTOR; CAPSID PROTEIN; CAPSID PROTEIN VP1, PARVOVIRUS B19; CYTOKINE; IL10 PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ERYTHEMA INFECTIOSUM; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; VIRAL CLEARANCE; ADULT; BLOOD; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN PARVOVIRUS B19; IMMUNOLOGY; MALE; MIDDLE AGED; MONONUCLEAR CELL; PARVOVIRUS INFECTION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; ARTHRITIS, RHEUMATOID; CAPSID PROTEINS; CONCANAVALIN A; CYTOKINES; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION;

EID: 85014897060     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2017.03.002     Document Type: Article

References (42)

1. [1] Firestein, G.S., Evolving concepts of rheumatoid arthritis. Nature 423 (2003), 356–361.
2. [2] Milla, F., Feliu, E., Ribera, J.M., Junca, J., Flores, A., Vidal, J., Zarco, M.A., Masat, T., Electron microscopic identification of parvovirus virions in erythroid and granulocytic-line cells in a patient with human parvovirus B19 induced pancytopenia. Leukemia Lymphoma 10 (1993), 483–487.
3. [3] Morey, A.L., Fleming, K.A., Immunophenotyping of fetal haemopoietic cells permissive for human parvovirus B19 replication in vitro. Br. J. Haematol. 82 (1992), 302–309.
4. [4] Soderlund-Venermo, M., Hokynar, K., Nieminen, J., Rautakorpi, H., Hedman, K., Persistence of human parvovirus B19 in human tissues. Pathologie-Biologie 50 (2002), 307–316.
5. [5] Kozireva, S.V., Zestkova, J.V., Mikazane, H.J., Kadisa, A.L., Kakurina, N.A., Lejnieks, A.A., Danilane, I.N., Murovska, M.F., Incidence and clinical significance of parvovirus B19 infection in patients with rheumatoid arthritis. J. Rheumatol. 35 (2008), 1265–1270.
6. [6] Takahashi, Y., Murai, C., Shibata, S., Munakata, Y., Ishii, T., Ishii, K., Saitoh, T., Sawai, T., Sugamura, K., Sasaki, T., Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 8227–8232.
7. [7] Oguz, F., Akdeniz, C., Unuvar, E., Kucukbasmaci, O., Sidal, M., Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis. J. Paediatr. Child Health 38 (2002), 358–362.
8. [8] Hsu, T.C., Tsay, G.J., Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 40 (2001), 152–157.
9. [9] Ramos-Casals, M., Cervera, R., Garcia-Carrasco, M., Vidal, J., Trejo, O., Jimenez, S., Costa, J., Font, J., Ingelmo, M., Cytopenia and past human parvovirus B19 infection in patients with primary Sjogren's syndrome. Semin. Arthritis Rheum. 29 (2000), 373–378.
10. [10] Lehmann, H.W., Lutterbuse, N., Plentz, A., Akkurt, I., Albers, N., Hauffa, B.P., Hiort, O., Schoenau, E., Modrow, S., Association of parvovirus B19 infection and Hashimoto's thyroiditis in children. Viral Immunol. 21 (2008), 379–383.
11. [11] Wang, J., Zhang, W., Liu, H., Wang, D., Wang, W., Li, Y., Wang, Z., Wang, L., Zhang, W., Huang, G., Parvovirus B19 infection associated with Hashimoto's thyroiditis in adults. J. Infect. 60 (2010), 360–370.
12. [12] Chapenko, S., Krumina, A., Logina, I., Rasa, S., Chistjakovs, M., Sultanova, A., Viksna, L., Murovska, M., Association of active human herpesvirus-6, -7 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv. Virol., 2012, 2012, 205085.
13. [13] Nikkari, S., Roivainen, A., Hannonen, P., Mottonen, T., Luukkainen, R., Yli-Jama, T., Toivanen, P., Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann. Rheum. Dis. 54 (1995), 597–600.
14. [14] Kerr, J.R., Cartron, J.P., Curran, M.D., Moore, J.E., Elliott, J.R., Mollan, R.A., A study of the role of parvovirus B19 in rheumatoid arthritis. Br. J. Rheumatol. 34 (1995), 809–813.
15. [15] Chen, Y.S., Chou, P.H., Li, S.N., Tsai, W.C., Lin, K.H., Tsai, K.B., Yen, J.H., Liu, H.W., Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan. J. Rheumatol. 33 (2006), 887–891.
16. [16] Caliskan, R., Masatlioglu, S., Aslan, M., Altun, S., Saribas, S., Ergin, S., Uckan, E., Koksal, V., Oz, V., Altas, K., Fresko, I., Kocazeybek, B., The relationship between arthritis and human parvovirus B19 infection. Rheumatol. Int. 26 (2005), 7–11.
17. [17] Tzang, B.S., Tsai, C.C., Tsay, G.J., Wang, M., Sun, Y.S., Hsu, T.C., Anti-human parvovirus B19 nonstructural protein antibodies in patients with rheumatoid arthritis. Clin. Chim. Acta; Int. J. Clin. Chem. 405 (2009), 76–82.
18. [18] Saal, J.G., Steidle, M., Einsele, H., Muller, C.A., Fritz, P., Zacher, J., Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol. Int. 12 (1992), 147–151.
19. [19] Kakurina, N., Kadisa, A., Lejnieks, A., Mikazane, H., Kozireva, S., Murovska, M., Use of exploratory factor analysis to ascertain the correlation between the activities of rheumatoid arthritis and infection by human parvovirus B19. Medicina 51 (2015), 18–24.
20. [20] Takasawa, N., Munakata, Y., Ishii, K.K., Takahashi, Y., Takahashi, M., Fu, Y., Ishii, T., Fujii, H., Saito, T., Takano, H., Noda, T., Suzuki, M., Nose, M., Zolla-Patzner, S., Sasaki, T., Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J. Immunol. 173 (2004), 4675–4683.
21. [21] Naciute, M., Mieliauskaite, D., Rugiene, R., Nikitenkiene, R., Jancoriene, L., Mauricas, M., Nora-Krukle, Z., Murovska, M., Girkontaite, I., Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis. J. Gen. Virol. 97 (2016), 3302–3312.
22. [22] Voll, R.E., Roth, E.A., Girkontaite, I., Fehr, H., Herrmann, M., Lorenz, H.M., Kalden, J.R., Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum. 40 (1997), 2162–2171.
23. [23] Kerr, J.R., Barah, F., Mattey, D.L., Laing, I., Hopkins, S.J., Hutchinson, I.V., Tyrrell, D.A., Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J. Gen. Virol. 82 (2001), 3011–3019.
24. [24] Ostler, T., Davidson, W., Ehl, S., Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur. J. Immunol. 32 (2002), 2117–2123.
25. [25] Stabler, T., Piette, J.C., Chevalier, X., Marini-Portugal, A., Kraus, V.B., Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum. 50 (2004), 3663–3667.
26. [26] Dolhain, R.J., ter Haar, N.T., Hoefakker, S., Tak, P.P., de Ley, M., Claassen, E., Breedveld, F.C., Miltenburg, A.M., Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br. J. Rheumatol. 35 (1996), 24–32.
27. [27] Cesario, T.C., Andrews, B.S., Martin, D.A., Jason, M., Treadwell, T., Friou, G., Tilles, J.G., Interferon in synovial fluid and serum of patients with rheumatic disease. J. Rheumatol. 10 (1983), 647–650.
28. [28] Petrovic-Rackov, L., Pejnovic, N., Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin. Rheumatol. 25 (2006), 448–452.
29. [29] Mosaad, Y.M., Metwally, S.S., Auf, F.A., Abd, E.L.S.E.R., el-Deek, B., Limon, N.I., el-Chennawi, F.A., Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. Egyptian J. Immunol./Egyptian Assoc. Immunol. 10 (2003), 19–26.
30. [30] Ebrahimi, A.A., Noshad, H., Sadreddini, S., Hejazi, M.S., Mohammadzadeh Sadigh, Y., Eshraghi, Y., Ghojazadeh, M., Serum levels of TNF-alpha, TNF-alphaRI, TNF-alphaRII and IL-12 in treated rheumatoid arthritis patients. Iranian J. Immunol.: IJI 6 (2009), 147–153.
31. [31] Yen, J.H., Chen, J.R., Tsai, W.J., Liu, H.W., Correlation of tumor necrosis factor alpha levels with disease activity of rheumatoid arthritis, Zhonghua Minguo wei sheng wu ji mian yi xue za zhi=. Chin. J. Microbiol. Immunol. 25 (1992), 232–243.
32. [32] Borzi, R.M., Arfilli, L., Focherini, M.C., Pulsatelli, L., Meliconi, R., Circulating tumor necrosis factor alpha in rheumatoid arthritis. Bollettino della Societa italiana di biologia sperimentale 69 (1993), 39–43.
33. [33] Manicourt, D.H., Triki, R., Fukuda, K., Devogelaer, J.P., Nagant de Deuxchaisnes, C., Thonar, E.J., Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheumatism 36 (1993), 490–499.
34. [34] Shimamoto, K., Ito, T., Ozaki, Y., Amuro, H., Tanaka, A., Nishizawa, T., Son, Y., Inaba, M., Nomura, S., Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J. Rheumatol. 40 (2013), 1074–1081.
35. [35] Oncul, O., Top, C., Ozkan, S., Cavuslu, S., Danaci, M., Serum interleukin 2 levels in patients with rheumatoid arthritis and correlation with insulin sensitivity. J. Int. Med. Res. 30 (2002), 386–390.
36. [36] Rivas, D., Mozo, L., Zamorano, J., Gayo, A., Torre-Alonso, J.C., Rodriguez, A., Gutierrez, C., Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. J. Autoimmun. 8 (1995), 587–600.
37. [37] Kerr, J.R., Cunniffe, V.S., Kelleher, P., Coats, A.J., Mattey, D.L., Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J. Med. Virol. 74 (2004), 147–155.
38. [38] Noble, A., Kemeny, D.M., Interleukin-4 enhances interferon-gamma synthesis but inhibits development of interferon-gamma-producing cells. Immunology 85 (1995), 357–363.
39. [39] Bermejo-Martin, J.F., Garcia-Arevalo, M.C., De Lejarazu, R.O., Ardura, J., Eiros, J.M., Alonso, A., Matias, V., Pino, M., Bernardo, D., Arranz, E., Blanco-Quiros, A., Predominance of Th2 cytokines. CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. Eur. Cytokine Network 18 (2007), 162–167.
40. [40] Gu, X., Li, P., Liu, H., Li, N., Li, S., Sakuma, T., The effect of influenza virus A on th1/th2 balance and alveolar fluid clearance in pregnant rats. Exp. Lung Res. 37 (2011), 445–451.
41. [41] Osakwe, C.E., Bleotu, C., Chifiriuc, M.C., Grancea, C., Otelea, D., Paraschiv, S., Petrea, S., Dinu, M., Baicus, C., Streinu-Cercel, A., Lazar, V., TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. Roum. Arch. Microbiol. Immunol. 69 (2010), 24–34.
42. [42] Cush, J.J., Splawski, J.B., Thomas, R., McFarlin, J.E., Schulze-Koops, H., Davis, L.S., Fujita, K., Lipsky, P.E., Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 38 (1995), 96–104.